EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline

EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications has closed an oversubscribed USD $21.5 million (UK £15.5m) Series A financing round. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities. The company was founded by EBS alumni Dr James McIlroy after recognising the therapeutic potential of the microbiome with the vision of building one of world’s leading microbiome drug development companies. 

Related posts

EBS to support a new breed of aspiring entrepreneurs

The team at EBS is excited to share details of our role in a ground-breaking new business creation programme. Createc, an advanced technology company headquartered in Cockermouth, Cumbria, has announced the launch of Fusion, a business creation programme for aspiring […]

Funding for alternative to animal testing

A near-£1 million investment will help University of Dundee spinout company Ten Bio Ltd to commercialise the human skin culture system it developed to provide a viable alternative for many experiments currently performed on animals. EBS provided advice and support […]